Compare ARI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | PGEN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2009 | 2013 |
| Metric | ARI | PGEN |
|---|---|---|
| Price | $10.92 | $4.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $11.00 | $8.33 |
| AVG Volume (30 Days) | 1.3M | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 9.31% | N/A |
| EPS Growth | ★ 183.51 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $271,589,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $68.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.39 | $1.26 |
| 52 Week High | $11.24 | $5.47 |
| Indicator | ARI | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 53.03 |
| Support Level | $9.59 | $4.02 |
| Resistance Level | $11.17 | $4.40 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 55.26 | 53.09 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.